Illustrative pack image. Actual packaging may differ.
FUZIM-CV Tablet
Enhanced Broad-Spectrum Antibiotic for Resistant Bacterial Infections
Composition
Cefuroxime Axetil 500 mg + Potassium Clavulanate 125 mg
- Prescription medicine
- Available to order
Overview
FUZIM-CV combines Cefuroxime Axetil, a second-generation cephalosporin antibiotic, with Potassium Clavulanate, a β-lactamase inhibitor. This synergistic combination provides potent bactericidal activity and overcomes resistance caused by β-lactamase-producing organisms.
Key Benefits
- Broad-spectrum coverage against gram-positive and gram-negative bacteria
- Effective against β-lactamase-producing resistant bacterial strains
- Ideal for moderate to severe bacterial infections
- Twice-daily dosing ensures effective plasma concentration and patient compliance
- Well-tolerated with a favorable safety profile
Indications
- Acute bacterial sinusitis
- Community-acquired pneumonia
- Chronic and acute bronchitis
- Complicated urinary tract infections
- Skin and soft tissue infections
- ENT infections (e.g., tonsillitis, otitis media)
